Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer.
about
Role of bone-anabolic agents in the treatment of breast cancer bone metastasesTrial Watch: Proteasomal inhibitors for anticancer therapyThe ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumorsOverview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Smart micelle@polydopamine core-shell nanoparticles for highly effective chemo-photothermal combination therapy.Disulfide cross-linked micelles of novel HDAC inhibitor thailandepsin A for the treatment of breast cancer.CIP2A is a target of bortezomib in human triple negative breast cancer cells.From bortezomib to other inhibitors of the proteasome and beyond.The RNA-binding protein Musashi-1 regulates proteasome subunit expression in breast cancer- and glioma-initiating cells.Emerging drugs in metastatic breast cancer: an update.Merlin: the wizard requires protein stability to function as a tumor suppressor.Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials.Clinical management of breast cancer heterogeneity.Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer
P2860
Q26822732-BBDF1C16-22C8-47E8-8670-CB56481BFAD2Q28082910-454B4D12-F49B-451E-BE99-9799CEE811C4Q34218976-13CC47E7-22BB-441F-8284-6BEA57FB6CF8Q34788381-EBBEF70E-2517-4C7B-8B89-2BD3C99152C4Q35837864-B80401F8-2E94-45A5-89F6-7A89CFA7DF4AQ35998436-22BF0399-C351-4830-A82B-9720652F2666Q36245640-25CD38EB-3A4E-46DD-917C-BB0244FCA06BQ36852277-CD7CF64E-B989-46DB-8AA0-1DD87340CBCCQ37670603-2298B093-78AC-4FC3-8D37-6CE01BAFBF1DQ37961957-45E65025-FE2E-4ADE-8D42-D3A337394B2AQ38023101-09CD3CBE-217D-4DC9-98D9-292ACCB730C1Q38258843-411D1CC1-CC12-4B7E-AA0E-3898C30FE893Q38431284-6EC38659-AB9D-48C5-9DE4-33A17DD690FDQ57106044-C4918469-5F3A-4B0C-861B-26D08B61656A
P2860
Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Phase II study of bortezomib a ...... t of metastatic breast cancer.
@en
Phase II study of bortezomib a ...... t of metastatic breast cancer.
@nl
type
label
Phase II study of bortezomib a ...... t of metastatic breast cancer.
@en
Phase II study of bortezomib a ...... t of metastatic breast cancer.
@nl
prefLabel
Phase II study of bortezomib a ...... t of metastatic breast cancer.
@en
Phase II study of bortezomib a ...... t of metastatic breast cancer.
@nl
P2093
P2860
P356
P1476
Phase II study of bortezomib a ...... t of metastatic breast cancer.
@en
P2093
Anastasia Ivanova
E Claire Dees
Frances A Collichio
Inge J Stijleman
Lisa A Carey
Philip S Bernard
William J Irvin
Wing-Keung Chiu
P2860
P304
P356
10.3816/CBC.2010.N.061
P407
P577
2010-12-01T00:00:00Z